

Agenda

16:00 CET	<p>Keynote</p> <p>The BRAINTEASER Project Officer at the European Health and Digital Executive Agency (HaDEA) will shed light on the importance of high quality, relevant and scientifically robust knowledge for impactful policymaking in the field.</p> <ul style="list-style-type: none">• Claudia Prettner, Project Adviser, European Health and Digital Executive Agency (HaDEA)
16:10 CET	<p>BRAINTEASER Results and Exploitation Challenges</p> <p>The BRAINTEASER Scientific Coordinator will present the most significant results of the project, highlighting key challenges in terms of exploitation with the aim of stimulating discussion.</p> <ul style="list-style-type: none">• Barbara Di Camillo, University of Padova, Information Engineering Department; BRAINTEASER Scientific Coordinator
16:20 CET	<p>Session 1: From lab to market - Unlocking the translation of research into brain innovation</p> <p>BRAINTEASER technology (which includes an app and low-cost wearables) was developed with and tested by people living with MS and ALS from 4 different cities: Madrid, Turin, Lisbon and Pavia. As the project comes to an end, the democratisation of BRAINTEASER solutions is a pressing issue. Session 1 will bring together key actors on the way from lab to the market to stress the power of collaboration to accelerate the translation of research into innovation.</p> <ul style="list-style-type: none">• Liesbet Geris, Professor, University of Liège, KU Leuven, VPHi; Research & Technology Working Group Leader, Avicenna Alliance• Elisabetta Vaudano, Principal Scientific Manager, Innovative Health Initiative (IHI)• Mats Sundgren, Senior Industry Scientific Director, European Institute for Innovation through Health Data (i~HD)
16:45 CET	<p>Session 2: From market to society - Enabling remote, value-based and patient-centred care</p> <p>BRAINTEASER has a mission to improve the quality of life of people living with MS and ALS and their caregivers through AI-based models enabling personalised early detection of patient complications and prediction of disease progression over time. What's the potential for our societies? Session 2 will provide a patient, clinical and industry perspective on remote, value-based and patient-centred care.</p> <ul style="list-style-type: none">• Elisabeth Kasilingam, CEO, European Multiple Sclerosis Platform (EMSP)

	<ul style="list-style-type: none"> • Leon Brudy, Business Development Manager EMEA, Garmin Health • Umberto Manera, Assistant Professor, Department of Neuroscience - University of Turin
17:10 CET	<p>Session 3: BRAINTEASER innovation showcase: the clinical app</p> <p>In session 3, BRAINTEASER clinical partners will introduce the audience to BRAINTEASER clinical app for MS and ALS. The session will also provide perspective on advancing clinical decision making in Parkinson's Disease and Dementia to foster the exchange of knowledge and experience for a better care of these conditions.</p> <ul style="list-style-type: none"> • Carlos de Miguel Sánchez, Neurologist, General University Hospital Gregorio Marañón • Ira Haraldsen, Head of Research Group, Oslo University Hospital; AI-Mind Project Coordinator • Eleonora Fiorenzato, Assistant Professor, University of Padova; HEREDITARY Representative
17:35 CET	<p>Session 4: BRAINTEASER exploitation roadmap - Key takeaways</p> <p>Session 4 aims to address the outcomes of a series of Focus Group meetings gathering BRAINTEASER community to enlarge the project's vision on users and market needs and obtain additional requirements to accompany the go-to market strategy towards the most suitable exploitation routes.</p> <ul style="list-style-type: none"> • Vincenzo Carbone, Senior R&I Project Manager, InSilicoTrials Technologies
17:40 CET	<p>Session 5: Open Discussion and Q&A</p>